source
- Biotech reverse mergers surge 1,600% in Q3, matching number of IPOs in 2026Biotech companies are turning to reverse mergers as a faster, less volatile route to the public markets. In the third quarter of 2026, 17 reverse mergers were completed or announced, a 1,600% incre…
- Novartis and BMS pause CAR-T trials after fatal immune syndrome casesNovartis has halted several immunology and neurology studies of its CAR T candidate rapcabtagene autoleucel after three patients experienced fatal immune effector cell‑associated hemophagocytic syn…